Welcome to our new, monthly resource roundup! Each month, we’ll be curating study opportunities, new clinical trials, research results, news articles, personal perspectives, and upcoming events of interest to women and families affected by breast, ovarian, or metastatic breast cancer.
Below are some links you might find useful.
Nutrition is an important factor for patients undergoing breast cancer treatment and recovery. The RadComp study wrote a blog post about some of the best foods you can eat during this critical time.
The PAN Foundation offers many resources to help patients connect with financial assistance to cover drugs and treatments. They recently launched the "Fund Finder," a web-based app designed to help underinsured and economically vulnerable patients with life-threatening, chronic or rare diseases quickly find financial assistance.
The Monarch E study is looking for patients who've been diagnosed with hormone receptor positive, HER2 negative early-stage breast cancer to participate in a new research study about endocrine therapy. Find out if you're eligible.
SHARE recently presented a program on conflicts of interest in breast cancer research and treatment. Read an overview of the event.
Researchers have discovered that women with simple ovarian cysts may not be at more risk for ovarian cancer than women with normal ovaries.
A new study from the International Journal of Cancer has found that epigenetic cervical cancer test outperforms Pap or human papillomavirus (HPV) test-based screening
MAGENTA Study from MD Anderson:
The MAGENTA study at MD Anderson offers free genetic testing to eligible participants with a family history of breast or ovarian cancer. See if you qualify.
Metastatic Breast Cancer:
Metastatic Trial Talk is a new resource guide that features carefully selected news and research about MBC each month including personal stories, resources and support, and information about clinical trials.
Have a resource you’d like to share in the next month’s roundup? Email [email protected]
Leave a comment below, or share your reaction on one of our online communities!